Merck, Inc.
🇵🇭Philippines
A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)
Phase 1
Completed
- Conditions
- Herpes Zoster
- Interventions
- Biological: V212Other: VZV Skin TestOther: Saline
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT00886613
A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 122
- Registration Number
- NCT00886600
Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 313
- Registration Number
- NCT00885352
A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)
Phase 2
Completed
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 246
- Registration Number
- NCT00885170
A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 576
- Registration Number
- NCT00882440
A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)
Phase 2
Completed
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2009-04-14
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT00880763
Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED)
- First Posted Date
- 2009-04-14
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 27
- Registration Number
- NCT00880568
Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 56
- Registration Number
- NCT00875056
Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 68
- Registration Number
- NCT00875394
A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)
Phase 1
Terminated
- Conditions
- Alzheimer's DiseaseDementia
- Interventions
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 4
- Registration Number
- NCT00874939
© Copyright 2025. All Rights Reserved by MedPath